Carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 (CYFRA 21-1) levels in induced sputum of lung cancer patients

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 7, 2008, Pages 542-547

  Hillas, G ^a   Moschos, C ^a   Dimakou, K ^a   Vlastos, F ^a   Avgeropoulou, S ^a   Christakopoulou, I ^b   Rasidakis, A ^a   Bakakos, P ^a  

^a Department of Respiratory and Critical Care Medicine ^*  (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Carcinoembryonic antigen; Cytokeratin fragment 19; Lung cancer; Neuron specific enolase; Sputum; Tumour markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPUTUM;

AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SENSITIVITY AND SPECIFICITY; SPUTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 55249095628     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701883172     Document Type: Article

References (26)

1. Diagnosis and management of lung cancer: ACCP evidence-based guidelines. Chest 2003;123 Suppl:1S-337S.
2. Ferrigno D, Buccheri G, Biggi A. Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J 1994;7:186-97.
3. Pastor A, Menendez R, Cremades MJ, Pastor V, Llopis R, et al. Diagnostic value of SCC, CEA and CYFRA 21-1 in lung cancer: a Bayesian analysis. Eur Respir J 1997;10:603-9.
4. Bates J, Rutherford R, Divilly M, et al. Clinical value of CYFRA 21-1, carcinoembryonic antigen, neurona-specific enolase, tissue polypeptide-specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir J 1997;10:2535-8.
5. Athanassiadou P, Psyhoyou H, Kyrkou K, Athanassiades P, Moulopoulos S. Expression of keratins and carcinoembryonic antigen in bronchial squamous metaplasma and lung carcinomas. Acta Cytol 1995;39:1161-6.
6. Ohwada A, Takahashi H, Nagaoka I, Iwabuchi K, Mikami O, et al. Effect of cigarette smoke on the mRNA and protein expression of carcinoembryonic antigen (CEA), a possible chemoattractant for neutrophils in human bronchioloalveolar tissues. Thorax 1995;50:651-7.
7. Cremades MJ, Menendez R, Pastor A, Llopis R, Aznar J. Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer. Respir Med 1998;92:766-71.
8. Trevisani L, Putinati S, Sartori S, Abbasciano V, Bagni B. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Chest 1996;109:104-8.
9. Sanguinetti CM, Riccioni G, Marchesani F, Pela R, Cecarini L. Bronchoalveolar lavage fluid level of carcinoembryonic antigen in the diagnosis of peripheral lung cancer. Monaldi Arch Chest Dis 1995;50:177-82.
10. Wesselius LJ, Dark DS, Papasian CJ. Airway carcinoembryonic antigen concentrations in patients with central lung cancer or chronic bronchitis. Chest 1990;98:393-7.
11. Stockley RA, Shaw J, Whitfield AG, Whitehead TP, Clarke CA, et al. Effect of cigarette smoking, pulmonary inflammation and lung disease on concentrations of carcinoembryonic antigen in serum and secretions. Thorax 1986;41:17-24.
12. Kalomenidis I, Dimakou K, Kolintza A, Vlami K, et al. Sputum carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 levels in lung cancer diagnosis. Respirology 2004;9:54-9.
13. Chanez P, Holz O, Ind PW, Djukanovic R, Maestrelli P, et al. Sputum induction. Eur Respir J 2002;20 Suppl 37:3S-8S.
14. Pizzichini E, Pizzichini MM, Leigh R, Djukanovic R, Sterk PJ. Safety of sputum induction. Eur Respir J 2002;37 Suppl:9S-18S.
15. Khajotia RR, Mohn A, Pokieser L, Schallescuak J, Vetter N. Induced sputum and cytological diagnosis of lung cancer. Lancet 1991;338:976-7.
16. Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25-9.
17. de Diego A, Compte L, Sanchis J, Enguidanos MJ, Marco J. Usefulness of carcinoembryonic antigen determination in bronchoalveolar lavage fluid. A comparative study among patients with peripheral lung cancer, pneumonia and healthy individuals. Chest 1991;100:1060-3.
18. Goldstein N, Lippmann ML, Goldberg SK, Fein AM, Shapiro B, et al. Usefulness of tumor markers in serum and bronchoalveolar lavage of patients undergoing fiberoptic bronchoscopy. Am Rev Respir Dis 1985;132:60-4.
19. Shitrit D, Zingerman B, Shitrit AB, Shiomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005;10:501-7.
20. Lai RS, Hsu HK, Lu JY, Ger LP, Lai NS. CYFRA 21-1 enzyme-linked immunosorbent assay: evaluation as a tumor marker in non-small cell lung cancer. Chest 1996;109:995-1000.
21. Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, et al. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur Respir J 1999;14:574-8.
22. Kanazawa H, Yoshikawa T, Yamada M, Shoji S, Fujii T, Kudoh S, et al. CYFRA 21-1, a cytokeratin subunit 19 fragment, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Clin Sci 1998;94:531-5.
23. Simpson JL, Gibson PG, Wark PAB. Optimization of sputum-processing methods for the measurement of interleukin-5: effects of protease inhibition. Respirology 2002;7:111-16.
24. Woolhouse IS, Bayley DL, Stockley RA. Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax 2002;57:667-71.
25. Sato M, Saito Y, Usuda K, Takahashi S, Sagawa M, et al. Occult lung cancer beyond bronchoscopic visibility in sputumcytology positive patients. Lung Cancer 1998;20:17-24.
26. Bechtel JJ, Petty TL, Saccomanno G. Five year survival and later outcome of patients with X-ray occult lung cancer detected by sputum cytology. Lung Cancer 2000;30:1-7.